
Cristina Messa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11236318/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007. Radiotherapy and Oncology, 2009, 91, 85-94.	0.3	321
2	Lymph Node Metastasis in Patients with Clinical Early-Stage Cervical Cancer: Detection with Integrated FDG PET/CT. Radiology, 2006, 238, 272-279.	3.6	292
3	Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 301-309.	3.3	258
4	Crizotinib in Anaplastic Large-Cell Lymphoma. New England Journal of Medicine, 2011, 364, 775-776.	13.9	256
5	Detection of Lymph-Node Metastases with Integrated [11C]Choline PET/CT in Patients with PSA Failure after Radical Retropubic Prostatectomy: Results Confirmed by Open Pelvic-Retroperitoneal Lymphadenectomy. European Urology, 2007, 52, 423-429.	0.9	232
6	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. European Urology, 2011, 60, 935-943.	0.9	209
7	Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients. Journal of the National Cancer Institute, 2014, 106, djt378.	3.0	207
8	Lung Regional Metabolic Activity and Gas Volume Changes Induced by Tidal Ventilation in Patients with Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1193-1199.	2.5	188
9	The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer. European Urology, 2011, 59, 51-60.	0.9	177
10	[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1065-1073.	3.3	171
11	Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. Nuclear Medicine Communications, 2007, 28, 589-595.	0.5	168
12	Integrated FDG PET/CT in Patients with Persistent Ovarian Cancer: Correlation with Histologic Findings. Radiology, 2004, 233, 433-440.	3.6	162
13	Lungs of patients with acute respiratory distress syndrome show diffuse inflammation in normally aerated regions: A [18F]-fluoro-2-deoxy-D-glucose PET/CT study. Critical Care Medicine, 2009, 37, 2216-2222.	0.4	160
14	[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 13-26.	3.3	147
15	PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1106-1116.	3.3	119
16	Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 932-939.	3.3	101
17	¹¹ C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy. Journal of Nuclear Medicine, 2014, 55, 233-241.	2.8	91
18	Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 472-479.	3.3	86

CRISTINA MESSA

#	Article	IF	CITATIONS
19	[¹¹ C]Choline Positron Emission Tomography/Computerized Tomography to Restage Prostate Cancer Cases With Biochemical Failure After Radical Prostatectomy and No Disease Evidence on Conventional Imaging. Journal of Urology, 2010, 184, 938-943.	0.2	74
20	Preoperative staging of cervical cancer: Is 18-FDG-PET/CT really effective in patients with early stage disease?. Gynecologic Oncology, 2011, 123, 236-240.	0.6	74
21	Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: A prospective study. Gynecologic Oncology, 2013, 131, 395-399.	0.6	66
22	Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: Results from a pathologically validated series. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 38.e9-38.e16.	0.8	61
23	Detection and compensation of organ/lesion motion using 4D-PET/CT respiratory gated acquisition techniques. Radiotherapy and Oncology, 2010, 96, 311-316.	0.3	54
24	Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiotherapy and Oncology, 2010, 96, 347-350.	0.3	49
25	[¹¹ C]Choline Positron Emission Tomography/Computerized Tomography for Early Detection of Prostate Cancer Recurrence in Patients with Low Increasing Prostate Specific Antigen. Journal of Urology, 2013, 189, 105-110.	0.2	42
26	Comparative evaluation of CT-based and respiratory-gated PET/CT-based planning target volume (PTV) in the definition of radiation treatment planning in lung cancer: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 702-710.	3.3	32
27	The role of PET/computed tomography scan in the management of prostate cancer. Current Opinion in Urology, 2011, 21, 230-236.	0.9	29
28	Time course of metabolic activity and cellular infiltration in a murine model of acid-induced lung injury. Intensive Care Medicine, 2012, 38, 694-701.	3.9	22
29	Imaging of lung inflammation during severe influenza A: H1N1. Intensive Care Medicine, 2010, 36, 717-718.	3.9	16
30	Quantification of Dynamic [18F]FDG Pet Studies in Acute Lung Injury. Molecular Imaging and Biology, 2016, 18, 143-152.	1.3	13
31	Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2011;59:572–83. European Urology, 2011, 60, e37-e38.	0.9	10
32	Carcinoma prostatico e ruolo della PET-TC. , 2010, , 163-169.		0